Background:
The soluble factor ps20 encoded by the human WFDC1 gene on Chromosome 16, is an ancient whey acidic protein (WAP) family member, characterized by highly evolutionarily conserved domain comprising eight cysteines that make 4 disulphide bonds. WAPs are soluble innate immune mediators implicated in homeostatic control of inflammation and broad anti-infective activities. Previous studies in our laboratory highlighted a novel function of ps20. We demonstrated ps20 expression in CD4-T cells, which rendered these cells highly susceptible to HIV infection through up-regulation of ICAM-1. Consistent with this observation, we showed that plasma ps20 levels positively correlated to CD4-T cell count. We also demonstrated that ps20 levels at the CD4-T cell level showed a strikingly inverse relationship with IFNg and silencing of ps20 in CD4-T cell clones led to upregulation of IFNg. This study was designed to further examine the role of ps20 in IFNg regulation in a chronic infection, such as TB, where IFNg levels are known to be impaired.
Methods & Materials: (i) An in-house ps20-specific sandwich ELISA was calibrated and used to confirm ps20 levels in plasma of 30 treatment naïve active TB, 15 TB treated (12 months post treatment), 12 IGRA+ and 10 IGRA-subjects.
(ii) To further test if raised plasma ps20 in active TB correlated with reduced IFNg expression, we measured the ps20 and IFNg mRNA and protein levels in PBMC cultured activated with PHA/IL-2 in time-course assays.
(iii) Rapamycin, a known regulator of the mTOR pathway is well established inhibitor of IFNg expression. We therefore used this regulator to further determine if suppression of IFNg leads to induction of ps20.
Results: (i) The ELISA data showed active TB subjects had a significantly higher (p = 0.0356) plasma ps20 compared to IGRA+ and IGRA-subjects.
(ii) PHA/IL-2 immunomodulation data confirm active TB subjects to have lower IFNg than IGRA+ and IGRA-subjects with concomitantly higher ps20 expression.
(iii) Rapamycin Inhibition assay confirms IFNg expression to be significantly reduced in the presence of Rapamycin with a concomitant marginal but consistent induction of ps20. The healthy human antibiotic resistome: a multi-body habitat analysis
Conclusion:
These studies highlight ps20 may be a novel regulator
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